The Briefing: Pepperdine’s Trademark Claim Against Netflix in “Running Point” Case Goes Under For Good
Episode 421 -- The Dangers of AI Mistakes
EEO-1 Reports, Remote Work, and Non-Compete Restrictions in Tennessee - Employment Law This Week®
The Briefing: UMG v. Quince: When Trending Audio Becomes Copyright Infringement
Unexpected Paths to IP Law with Kevin MacDonald
New Preorder Patent Owner Rights in Ex Parte Reexamination — Patents: Post-Grant Podcast
The Briefing: Documentary Fair Use After Warhol: The Tenth Circuit Gets It Right
Words Matter: How to Draft Arbitration Agreements That Hold Up in Court - Employment Law This Week®
SkadBytes Podcast | AI Regulation: EU and UK Update and What It Means in Practice
The Briefing: Frida Kahlo vs. The 11th Circuit - A Warning for IP Owners Everywhere
Navigating ICE’s Updated I-9 Audit Guidelines: What Employers Need to Know
At the Intersection of Biotech and AI with Janice Vatland
Podcast - De genérica a icónica: El glow up de una marca
JONES DAY PRESENTS®: Cross-Border Trade Secret Litigation in the U.S. Courts
How Did James Bond Spark a 50-Year Legal War Over Who Owns 007? — No Infringement Intended Podcast
Episode 406 -- AI Risks and Compliance: Building a Governance Framework
The Briefing: Taylor Swift, Trademark Law, and the Fight Over ‘Life of a Showgirl’
DOJ’s Bulk Sensitive Data Transfer Rule: Key Insights for Health Care Compliance Teams – Diagnosing Health Care
SBR-Author’s Podcast: Bribery Beyond Borders: The Hidden History and Future of the FCPA with Severin Wirz
'Urgent National Action to Save College Sports': Trump’s NIL Playbook — Highway to NIL Podcast
Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889 - Introduction - Yesterday, the Supreme Court held in a unanimous 9-0 decision that induced patent infringement requires active steps to encourage...more
On May 28, 2026, the US Court of Appeals for the Federal Circuit overturned a $59 million damages award for trade secret misappropriation under the Defend Trade Secrets Act (“DTSA”) on statute of limitations grounds....more
On June 4, 2026, the Supreme Court of the United States issued three decisions: Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., Case No. 24-889: This patent dispute addresses when a generic drug manufacturer may...more
A unanimous Supreme Court reversed the Federal Circuit and held that Amarin did not plausibly allege that Hikma’s skinny label and marketing actively induced infringement of Vascepa’s cardiovascular-use patents — a decisive...more
Schedule A litigation has become a prominent tool for intellectual property owners to effectively enforce their rights against entities misappropriating their trademarks, copyrights, and/or patented inventions through the...more
Artificial intelligence (AI) has moved rapidly from an emerging technology to a foundational component of modern business operations. With that growth has come an expanding set of intellectual property (IP) disputes....more
Patagonia has spent more than fifty years building a brand that stands for something beyond outdoor apparel. Its reputation for environmental activism, corporate accountability, and progressive values is not incidental to its...more
Eligibility wins at the Federal Circuit are scarce enough that any decision finding a claim to survive § 101 is worth a read. Constellation Designs, LLC v. LG Electronics Inc. is worth two reads, because the panel managed to...more
Adalimumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...more
When an employee leaves to join a competitor, the former employer may have concerns that the employee will use its proprietary and confidential business information to assist that competitor. ...more
Rituximab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...more
On June 4, 2026, the U.S. Supreme Court held in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889, that routine generic drug marketing activities, including skinny labels, standard therapeutic equivalence...more
The United States Patent and Trademark Office (USPTO) has introduced a new “Pre-Docketing Notice” pilot program aimed at improving transparency and efficiency in the patent examination process. Under this program, applicants...more
A growing body of law indicates that inputting proprietary information into public artificial intelligence tools may undermine the reasonable measures and confidentiality requirements that are central to trade secret...more
The UK government introduced a new Sporting Events Bill in the House of Lords on 14 May 2026 (the Bill), intending to establish a permanent UK-wide legal framework to streamline delivery of major international sporting...more
Contributory copyright liability for e-commerce platforms is in flux after the Supreme Court's recent ruling in Cox Communications, Inc. v. Sony Music Ent, 146 S. Ct. 959 (2026). The decision narrows years of precedent...more
As excitement builds for the upcoming UFC Freedom 250 event scheduled to take place on the South Lawn of the White House in Washington, D.C., Vondran Legal is issuing this advisory to bars, restaurants, taverns, sports...more
My colleagues published an excellent eUpdate on a number of trade developments this week. It’s been a lot, with USTR coming out with a slate of new 301 Tariffs following its investigation into forced labor related policies...more
Biosimilar Litigations include litigations relating to biosimilar/follow-on products of CDER-listed reference products. Litigations between biosimilar applicants/manufacturers and reference product sponsors as well as...more
Pepperdine has used the “Waves” name for its athletic teams since 1937. Netflix’s Running Point also features a fictional basketball team called the Waves. In this episode of The Briefing, Weintraub Tobin Partners Scott...more
Insulin Glargine Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...more
The Supreme Court issued its decision today in Hikma Pharmaceuticals v. Amarin Pharma, addressing what it takes to successfully plead a claim for indirect patent infringement...more
With the news out of the Western District of Texas, TalKing IP caught up with K&S’s own Judge (Ret.) Lee Yeakel to ask a few questions about the news and what he sees happening in the District. Judge Yeakel served on the...more
In a unanimous decision handed down today, the Supreme Court delivered a tactical victory for Hikma, and a measure of guidance for other generic manufacturers. In Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No....more
Today, the U.S. Supreme Court issued its decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889, unanimously reversing the Federal Circuit and holding that Amarin failed to state a claim “more than a...more